Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 25, 2022 05:06 ET | Source: Shanghai Ark Biopharmaceutical Co., Ltd.

爱科百发宣布完成抗呼吸道合胞病毒新药齐瑞索韦的III期临床试验全部患者入组和用药治疗

SHANGHAI, China, Jan. 25, 2022 (GLOBE NEWSWIRE) --...
January 25, 2022 05:06 ET | Source: Shanghai Ark Biopharmaceutical Co., Ltd.

ArkBio Announces Completion of Patient Enrollment and Dosing in AIRFLO, a Phase III Registration Trial of Ziresovir for Treatment of Respiratory Syncytial Virus Infection

SHANGHAI, China, Jan. 25, 2022 (GLOBE NEWSWIRE) -- On January 25, 2022, Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced the completion of patient enrollment and dosing of ziresovir...
June 10, 2021 07:20 ET | Source: Arch Biopartners

Arch Biopartners Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation

TORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
December 08, 2020 07:00 ET | Source: uniQure Inc.

uniQure Presents Late-Breaking Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B at the 62nd Annual Meeting of the American Society of Hematology

~ First primary endpoint in study met with mean Factor IX activity of 37% of normal at 26 weeks ~ ~ Data show 91% reduction in reported bleeds requiring treatment, with 87% of patients reporting no...
November 30, 2020 07:05 ET | Source: uniQure Inc.

uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting

~ Strong Presence at ASH Featuring Five Presentations, Including Late-BreakingOral Presentation on HOPE-B Pivotal Trial ~ ~ uniQure to Host Investor Webcast Tuesday, December 8, 2020 at 5:00 p.m. ET...
November 19, 2020 09:10 ET | Source: uniQure Inc.

uniQure Announces Positive Top-Line Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B

~ Phase III study in 54 patients met primary endpoint with mean Factor IX activity of 37% of normal at 26 weeks ~ ~ Patients achieved significant increases in Factor IX activity irrespective of...
January 17, 2019 02:00 ET | Source: PledPharma AB

PledPharma presenterar läkemedelskandidaten PledOx® fas III-program på global cancerkonferens

Stockholm, 17 januari 2019. PledPharma AB (publ) meddelar att bolagets globala fas III-program, POLAR, för PledOx® har accepterats för poster-presentation på den globala konferensen Gastrointestinal...
January 17, 2019 02:00 ET | Source: PledPharma AB

PledPharma presents PledOx®’s phase III program at the Gastrointestinal (GI) Cancers Symposium

Stockholm, January 17, 2019. PledPharma AB (publ) announces that the company’s global phase III program, POLAR, has been accepted for a poster presentation during the Gastrointestinal (GI) Cancers...
January 10, 2019 02:00 ET | Source: PledPharma AB

PledPharma erhåller 600 MJPY, cirka 49 MSEK, i samband med inklusion av den första asiatiska patienten i det globala fas III programmet för PledOx®

Stockholm, 10 januari 2019. PledPharma AB (publ) och Solasia Pharma K.K. meddelar att den första patienten i Japan har inkluderats till det globala fas III‑programmet för läkemedelskandidaten PledOx®....
January 10, 2019 02:00 ET | Source: PledPharma AB

First Asian patient has been included in the global Phase III program for PledOx® and will trigger a milestone payment of 600 MJPY (c.49 MSEK) to PledPharma

Stockholm, January 10, 2019. PledPharma AB (publ) and Solasia Pharma K.K. announces that the first patient has been included in the global Phase III program for the drug candidate PledOx® in Japan....

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right